These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 35128617

  • 1. The Effect of N-Acetyl-DL-Leucine on Neurological Symptoms in a Patient with Ataxia-Telangiectasia: a Case Study.
    Saberi-Karimian M, Beyraghi-Tousi M, Mirzadeh M, Gumpricht E, Sahebkar A.
    Cerebellum; 2023 Feb; 22(1):96-101. PubMed ID: 35128617
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of N-acetyl-L-leucine in patients with ataxia telangiectasia: A randomized, double-blind, placebo-controlled, crossover clinical trial.
    Beyraghi-Tousi M, Sahebkar A, Houra M, Sarvghadi P, Jamialahmadi T, Bagheri R, Tavallaie S, Gumpricht E, Saberi-Karimian M.
    Eur J Paediatr Neurol; 2024 May; 50():57-63. PubMed ID: 38669738
    [Abstract] [Full Text] [Related]

  • 3. The Effects of N-Acetyl-L-Leucine on the Improvement of Symptoms in a Patient with Multiple Sulfatase Deficiency.
    Saberi-Karimian M, Houra M, Jamialahmadi T, Sarvghadi P, Nikbaf M, Akhlaghi S, Sahebkar A.
    Cerebellum; 2023 Dec; 22(6):1250-1256. PubMed ID: 36482027
    [Abstract] [Full Text] [Related]

  • 4. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.
    Feil K, Adrion C, Teufel J, Bösch S, Claassen J, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Stendel C, Uslar E, van de Warrenburg B, Berger I, Naumann I, Bayer O, Müller HH, Mansmann U, Strupp M.
    BMC Neurol; 2017 Jan 10; 17(1):7. PubMed ID: 28068987
    [Abstract] [Full Text] [Related]

  • 5. Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
    Feil K, Adrion C, Boesch S, Doss S, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Schöls L, Steiner KM, Stendel C, Timmann D, Naumann I, Mansmann U, Strupp M, ALCAT Study Group.
    JAMA Netw Open; 2021 Dec 01; 4(12):e2135841. PubMed ID: 34905009
    [Abstract] [Full Text] [Related]

  • 6. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series.
    Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg BP, Klopstock T, Feil K.
    J Neurol; 2013 Oct 01; 260(10):2556-61. PubMed ID: 23835634
    [Abstract] [Full Text] [Related]

  • 7. Effects of Acetyl-DL-Leucine on Ataxia and Downbeat-Nystagmus in Six Patients With Ataxia Telangiectasia.
    Brueggemann A, Bicvic A, Goeldlin M, Kalla R, Kerkeni H, Mantokoudis G, Abegg M, Kolníková M, Mohaupt M, Bremova-Ertl T.
    J Child Neurol; 2022 Jan 01; 37(1):20-27. PubMed ID: 34620022
    [Abstract] [Full Text] [Related]

  • 8. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.
    Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill GC, Davis W, Evans W, Flint S, Galione A, Granzer U, Greenfield J, Karl R, Kay R, Lewi D, Mathieson T, Meyer T, Pangonis D, Platt FM, Tsang L, Verburg C, Factor M, Strupp M.
    Trials; 2021 Jan 22; 22(1):84. PubMed ID: 33482890
    [Abstract] [Full Text] [Related]

  • 9. Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders.
    Kalla R, Strupp M.
    Curr Neuropharmacol; 2019 Jan 22; 17(1):7-13. PubMed ID: 30182858
    [Abstract] [Full Text] [Related]

  • 10. Acetyl-dl-leucine in Niemann-Pick type C: A case series.
    Bremova T, Malinová V, Amraoui Y, Mengel E, Reinke J, Kolníková M, Strupp M.
    Neurology; 2015 Oct 20; 85(16):1368-75. PubMed ID: 26400580
    [Abstract] [Full Text] [Related]

  • 11. N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study.
    Fields T, M Bremova T, Billington I, Churchill GC, Evans W, Fields C, Galione A, Kay R, Mathieson T, Martakis K, Patterson M, Platt F, Factor M, Strupp M.
    Trials; 2023 May 29; 24(1):361. PubMed ID: 37248494
    [Abstract] [Full Text] [Related]

  • 12. Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series.
    Schniepp R, Strupp M, Wuehr M, Jahn K, Dieterich M, Brandt T, Feil K.
    Cerebellum Ataxias; 2016 May 29; 3():8. PubMed ID: 27073690
    [Abstract] [Full Text] [Related]

  • 13. Acetyl-DL-leucine in cerebellar ataxia ([18F]-FDG-PET study): how does a cerebellar disorder influence cortical sensorimotor networks?
    Becker-Bense S, Kaiser L, Becker R, Feil K, Muth C, Albert NL, Unterrainer M, Bartenstein P, Strupp M, Dieterich M.
    J Neurol; 2023 Jan 29; 270(1):44-56. PubMed ID: 35876876
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Evaluation of Low-Dose Betamethasone for Ataxia Telangiectasia.
    Hasegawa S, Kumada S, Tanuma N, Tsuji-Hosokawa A, Kashimada A, Mizuno T, Moriyama K, Sugawara Y, Shirai I, Miyata Y, Nishida H, Mashimo H, Hasegawa T, Hosokawa T, Hisakawa H, Uematsu M, Fujine A, Miyata R, Sakuma H, Kashimada K, Imai K, Morio T, Hayashi M, Mizutani S, Takagi M.
    Pediatr Neurol; 2019 Nov 29; 100():60-66. PubMed ID: 31272782
    [Abstract] [Full Text] [Related]

  • 15. The Latest Developments for the Treatment of Ataxia Telangiectasia: A Narrative Review.
    Mehri A, Toosi MB, Tavasoli AR, Saberi-Karimian M.
    Cerebellum; 2024 Dec 29; 23(6):2607-2615. PubMed ID: 39327359
    [Abstract] [Full Text] [Related]

  • 16. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
    Feil K, Bremova T, Muth C, Schniepp R, Teufel J, Strupp M.
    Cerebellum; 2016 Feb 29; 15(1):38-42. PubMed ID: 26519380
    [Abstract] [Full Text] [Related]

  • 17. Minimum effective betamethasone dosage on the neurological phenotype in patients with ataxia-telangiectasia: a multicenter observer-blind study.
    Cirillo E, Del Giudice E, Micheli R, Cappellari AM, Soresina A, Dellepiane RM, Pietrogrande MC, Dell'Era L, Specchia F, Pession A, Plebani A, Pignata C.
    Eur J Neurol; 2018 Jun 29; 25(6):833-840. PubMed ID: 29489040
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia.
    Broccoletti T, Del Giudice E, Cirillo E, Vigliano I, Giardino G, Ginocchio VM, Bruscoli S, Riccardi C, Pignata C.
    Eur J Neurol; 2011 Apr 29; 18(4):564-70. PubMed ID: 20840352
    [Abstract] [Full Text] [Related]

  • 19. Correlation Between the SARA and A-T NEST Clinical Severity Scores in Adults with Ataxia-Telangiectasia.
    Major T, Tiet MY, Horvath R, Hensiek AE.
    Cerebellum; 2024 Apr 29; 23(2):455-458. PubMed ID: 37036622
    [Abstract] [Full Text] [Related]

  • 20. Failure to confirm benefit of acetyl-DL-leucine in degenerative cerebellar ataxia: a case series.
    Pelz JO, Fricke C, Saur D, Classen J.
    J Neurol; 2015 May 29; 262(5):1373-5. PubMed ID: 25862484
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.